Mechanisms of tumor metastasis to the bone: Challenges and opportunities

Journal of Bone and Mineral Research

Volumn 18, Issue 2, 2003, Pages 190-194

  Reddi, A Hari ^a,d   Roodman, David ^b   Freeman, Colette ^c   Mohla, Suresh ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone morphogenetic proteins; Breast; Myeloma; Parathyroid hormone; Prostate

Indexed keywords

BONE ATROPHY; BONE DEVELOPMENT; BONE MATRIX; BONE METASTASIS; BONE PAIN; BREAST CARCINOMA; CANCER MORTALITY; CARCINOGENESIS; DEATH; HUMAN; METASTASIS; MORBIDITY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOSCLEROSIS; PATHOLOGIC FRACTURE; PROSTATE CARCINOMA; REVIEW;

ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BREAST NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NEOPLASM METASTASIS; OSTEOBLASTS; OSTEOCLASTS; PARATHYROID HORMONE; PROSTATIC NEOPLASMS;

EID: 0037302045     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.2.190     Document Type: Review

References (30)

1. Goltzman D 2001 Extending preclinical models of skeletal manifestations of malignancy to the clinical setting. Semin Oncol 4(Suppl 11):9-14.
2. Weber MH, Goltzman D, Kostenuik P, Rabbani S, Singh G, Duivenvoorden WC, Orr FW 2000 Mechanisms of tumor metastasis to bone. Crit Rev Eukaryot Gene Expr 10:281-302.
3. Boyce BF, Yoneda T, Guise TA 1999 Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 6:333-347.
4. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T 2000 Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88(Suppl 12):2979-2988.
5. Roodman GD 2001 Biology of osteoclast activation in cancer. J Clin Oncol 19:3562-3571.
6. Chirgwin JM, Guise TA 2000 Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10:159-178.
7. Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R 2001 Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer 93:507-515.
8. Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW 2001 A conditional replication-competent adenoviral vector, Ad-OC-Ela, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 61:6012-6019.
9. Zhau HE, Li CL, Chung LW 2000 Establishment of human prostate carcinoma skeletal metastasis models. Cancer 88(Suppl 12):2995-3001.
10. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y 2001 Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98:11581-11586.
11. Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS 2001 Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 7:4262-4271.
12. Shain KH, Landowski TH, Dalton WS 2000 The tumor microenvironment as a determinant of cancer cell survival: A possible mechanism for de novo drug resistance. Curr Opin Oncol 12:557-563.
13. Feng X, Novack DV, Faccio R, Ory DS, Aya K, Boyer MI, McHugh KP, Ross FP, Teitelbaum SL 2001 A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. J Clin Invest. 107:1137-1144.
14. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ 2001 Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432-4436.
15. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW 2000 Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6:521-528.
16. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP 2000 Molecular mechanisms of cancer pain. Nat Rev Cancer 2:201-209.
17. Ilic D, Genbacev O, Jin F, Caceres E, Almeida EA, Bellingard-Dubouchaud V, Schaefer EM, Damsky CH, Fisher SJ 2001 Plasma membrane-associated pY397FAK is a marker of cytotrophoblast invasion in vivo and in vitro. Am J Pathol 159:93-108.
18. Bianco P, Riminucci M, Gronthos S, Robey PG 2001 Bone marrow stromal stem cells: Nature, biology, and potential applications. Stem Cells 19:180-192.
19. Reddi AH, Huggins C 1972 Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc Natl Acad Sci USA 69:1601-1605.
20. Reddi AH 1998 Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 16:247-252.
21. Jacob K, Webber M, Benayahu D, Kleinman HK 1999 Osteonectin promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone. Cancer Res 59:4453-4457.
22. Lin J, Hutchinson L, Gaston SM, Raab G, Freeman MR 2001 BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: A unique role for proHB-EGF in cell survival regulation. J Biol Chem 276:30127-30132.
23. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R 2001 TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 20:2254-2272.
24. Koike C, Chao DT. Zetter BR 1999 Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells. Cancer Res 59:6109-6112.
25. Ducy P, Karsenty G 1998 Genetic control of cell differentiation in the skeleton. Curr Opin Cell Biol 10:614-619.
26. Bodine PV, Komm BS 1999 Evidence that conditionally immortalized human osteoblasts express an osteocalcin receptor. Bone 25:535-543.
27. Stein GS, Lian JB, van Wijnen AJ, Stein JL 1997 The osteocalcin gene: A model for multiple parameters of skeletal-specific transcriptional control. Mol Biol Rep 24:185-196.
28. Koeneman KS, Kao CH, Ko SC, Yang L, Wada Y, Kallmer DF, Gillenwater JY, Zhau HY, Chung LW. Gardner TA 2000 Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 18:102-110.
29. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S 1996 Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705.
30. Papapoulos SE, Hamdy NA, van der Pluijm G 2000 Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer 88(Suppl 12):3047-3053.